title: [Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs].
abstract: Despite significant progress in the discovery and design of drugs, the interindividual variability to the standard dose of a given drug remains a serious problem in clinical practice. In the future, the aim of pharmacogenetic is to provide new strategies for optimizing drug therapy, both in terms of efficacy and safety. The clinical validation of an increasing number of pharmacogenetic tests, as well as the development of new highly efficient technologies should further promote pharmacogenetics in clinical practice and lead to the optimization and individualization, before treatment, of drug therapy. Therapeutic drug monitoring is a valid tool to determine the pharmacokinetic of a drug and individualized drug therapy, adjusting patient's dose requirement through the measurement and interpretation of drug concentrations. Thus, phenotyping and genotyping tests are now available that determine or predict the metabolic status of an individual and enable the evaluation of risk of drug failure or toxicity. Based on clinical applications, this review focuses on interest of pharmacogenetics, in combination with anticancer agents TDM, on the individualization of treatments used in oncology.
authors.affiliation: Service de pharmacocinétique et toxicologie, Laboratoire de biologie médicale, Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital de la Timone, Marseille, France.
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Chantry
authors.affiliation: Service de pharmacocinétique et toxicologie, Laboratoire de biologie médicale, Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital de la Timone, Marseille, France.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Quaranta
authors.affiliation: Service de pharmacocinétique et toxicologie, Laboratoire de biologie médicale, Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital de la Timone, Marseille, France.
authors.forename: Joseph
authors.initials: J
authors.lastname: Ciccolini
authors.affiliation: Service de pharmacocinétique et toxicologie, Laboratoire de biologie médicale, Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital de la Timone, Marseille, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Lacarelle
mesh_terms: D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D005472:Fluorouracil / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D008727:Methotrexate / Q000493:pharmacokinetics / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D013629:Tamoxifen / Q000493:pharmacokinetics / Q000627:therapeutic use; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D013629:Tamoxifen; D003841:Deoxycytidine; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin; D008727:Methotrexate; D000093542:Gemcitabine
keywords: anticancer drugs; pharmacogenetic; pharmacokinetic; polymorphism; therapeutic drug monitoring